Commentary 1 on: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C, Ling M, Lebwohl M, et al
J Am Acad Dermatol. 2004;51:731-738.
Question 1: What is the response of intertriginous psoriasis to topical pimecrolimus in comparison with vehicle?
Design: Randomized, participant- and outcome-evaluator–masked, vehicle-controlled trial.
Bigby M. Pimecrolimus and Tacrolimus for the Treatment of Intertriginous and Facial PsoriasisAre They Effective?. Arch Dermatol. 2005;141(9):1152-1153. doi:10.1001/archderm.141.9.1152